Related Experiment Videos
Serum cholesterol and serotonergic function in major depressive disorder
George I Papakostas1, Timothy Petersen, David Mischoulon
1Depression Clinical and Research Program, Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, 15 Parkman Street, WAC 812, Boston, MA 02114, USA. gpapakostas@partners.org
Psychiatry Research
|June 12, 2003
Summary
Major depressive disorder (MDD) patients with high cholesterol showed blunted cortisol responses to DL-fenfluramine, suggesting impaired serotonergic function. Elevated cholesterol may negatively impact treatment outcomes in MDD.
Area of Science:
- Neuroscience
- Psychiatry
- Biochemistry
Background:
- Serum cholesterol levels correlate with serotonergic (5HT) function in healthy adults.
- Major depressive disorder (MDD) patients may exhibit altered cholesterol levels and poorer treatment prognosis with elevated cholesterol.
- Understanding the interplay between cholesterol and 5HT function in MDD is crucial for predicting treatment response.
Purpose of the Study:
- To investigate the relationship between serum cholesterol and central 5HT function in MDD patients.
- To compare 5HT function between MDD patients with and without elevated cholesterol.
- To assess the predictive value of cholesterol levels on neuroendocrine responses to DL-fenfluramine.
Main Methods:
- Fasting serum cholesterol levels were measured in 21 MDD outpatients.
- Cortisol and prolactin responses to DL-fenfluramine (60 mg oral) were measured.
- Patients were categorized based on elevated cholesterol (> /=200 mg/dl).
Main Results:
- MDD patients with elevated cholesterol demonstrated a more attenuated cortisol response to DL-fenfluramine.
- No significant relationship was found between cholesterol levels and prolactin response.
- Cholesterol levels did not predict the degree of cortisol or prolactin response.
Conclusions:
- Elevated cholesterol may impair central serotonergic function in MDD patients, indicated by attenuated neuroendocrine responses.
- This impairment could explain poorer treatment response and higher relapse rates in MDD patients with high cholesterol.
- Further research is warranted to explore cholesterol-lowering interventions for improving MDD treatment outcomes.